ClinicalTrials.gg
TerminatedNCT01227512SALACIAUpdated Oct 30, 2014Results posted

Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia

A Phase 3 interventional study of tolvaptan and Fluid Restriction in Hyponatremia, Dilutional Hyponatremia and Inappropriate ADH Syndrome, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Terminated at 56 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-30.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
Recruitment challenges and results of interim futility analysis, which showed less than likely to achieve primary endpoint goal-length of hospital stay.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
124
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing tolvaptan in Hyponatremia — none open to participants now, none under way, none of them phase 3. Tolvaptan · Hyponatremia.

Enrollment
5th of 20
124 · median 55
Started
2010
the only one that year
Phase 3
9 of 20
none open now
Registered
6th of 20
by date
Lead sponsor
8 of 20
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 20 studies testing tolvaptan in Hyponatremia, this one is the 5th largest by enrollment, is the only one that started in 2010, is one of 9 in phase 3, and was the 6th registered.

Hyponatremia

164 studies on the registry are indexed under Hyponatremia; 16 are open to participants now.

Browse Hyponatremia studies →

Open to participants now

None of the 20 studies testing tolvaptan in Hyponatremia is open now. The open studies under Hyponatremia, anywhere →

About tolvaptan

Tolvaptan: first FDA approval 2009 (SAMSCA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Hyponatremia studies recruiting now, 13 (93%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing tolvaptan in Hyponatremia as a file.
02

Study summary

The purpose of this study is to determine if hospitalized patients with symptomatic hyponatremia treated with tolvaptan are in the hospital for less time than patients treated with fluid restriction. The study will also test if tolvaptan is better than fluid restriction in treating the symptoms of hyponatremia in hospitalized patients.

03

Conditions studied

  • Hyponatremia
  • Dilutional Hyponatremia
  • Inappropriate ADH Syndrome

Keywords

  • Hyponatremia
  • Dilutional Hyponatremia
  • Euvolemic Hyponatremia
  • Hypervolemic Hyponatremia
  • Fluid Restriction
  • Tolvaptan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hyponatremia in clinically euvolemic or hypervolemic states, defined as serum sodium \< 130 mEq/L prior to randomization
  • symptoms of hyponatremia, defined as a CGI-S score between 3-6, inclusive
  • Female subjects of child bearing potential who agree to remain abstinent or to practice double-barrier forms of from screening through 30 days following first dose on IMP

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or breast feeding, and females of who are not using acceptable methods (such as barrier contraceptives or methods that result in a failure rate of less than 1%)
  • Hyponatremia in hypovolemic states, defined as the presence of clinical and historical evidence of extracellular fluid volume depletion, including but not limited to skin turgor, orthostatic changes in blood pressure or heart rate, dry mucous membranes, or a response to IV saline challenge
  • Subjects who are likely to require prolonged hospitalization for reasons other than hyponatremia, eg. new femoral fracture, surgeries requiring extended recovery
  • Recent prior treatment for hyponatremia: hypertonic saline (including normal saline challenge) (within 8 hours of baseline) or urea, lithium, demeclocycline, conivaptan or tolvaptan (within 4 days of baseline). Includes any treatment, other than fluid restriction for the purpose of increasing serum sodium.
  • Hyponatremia symptoms of a severity (eg, CGI = 7) such that they require immediate intervention with hypertonic saline; or are expected to require such therapy within 48 hours
  • Causes of neurological symptoms which are attributable to psychological (psychosis), structural (dementia of the Alzheimer's type, stroke, , multi-infarct dementia) or other metabolic causes (eg. hyper- or hypo-: oxemia, glycemia, calcemia, ammonemia, etc)
  • Acute and transient hyponatremia associated with head trauma or severe neurological injury (eg. stroke, subdural hematoma)or the use of recreational drugs.
  • History of hyponatremia known to be due to severe, untreated hypothyroidism/adrenal insufficiency
  • Subjects with psychogenic polydipsia
  • Systolic arterial blood pressure \< 90 mmHg at screening
  • History of and/or idiosyncratic reaction to benzazepine or benzazepine derivatives (such as benazepril), or tolvaptan
  • History of drug or medication abuse within the 3 months prior to screening, or current alcohol abuse
  • Uncontrolled diabetes mellitus defined as glucose > 300 mg/dL [16.7 mmol/L]
  • Current urinary tract obstruction (eg, obstructive benign prostatic hypertrophy)
  • Current condition of anuria
  • Serum creatinine > 3.5 mg/dL at screening
  • Terminally ill or moribund condition with little chance of short-term (eg, 30 day) survival
  • Subjects whose hyponatremia is the result of any medication that can safely be withdrawn (examples of drugs often not withdrawn include: anticonvulsants [eg, carbamazepine] and antipsychotics [eg, haloperidol])
  • Patients receiving DDAVP within 2 days of screening
  • Patients with history of active variceal bleeding within the past 30 days, without prior approval from sponsor medical monitor
  • Participation in another drug trial within the past 30 days
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Tolvaptan 15-60mg

    Oral tablet without fluid restriction. After the initial dose, daily dose may be titrated based on response.

    Drug: tolvaptan

  • Active comparator
    Fluid Restriction

    Placebo tablet with prescribed fluid restriction. After the initial dose, level of fluid restriction may titrated based response.

    Other: Fluid Restriction

Interventions

  • 15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.

    Also known as: SAMSCA, OPC-41061, OPC-156

  • OtherFluid Restriction

    Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response. Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo "dose"

06

What researchers measure

Primary outcomes

  1. Length of Hospital Stay (LoS)

    LoS was time to clinically ready to be hospital discharged (CRBD) from study treatment initiation, disregarding prolonged hospitalization due solely to social factors.

    Time frame: 45 days

Secondary outcomes

  1. Change From Baseline to 48 Hour Post Dose in Clinical Global Impression-Severity (CGI-S) of Hyponatremia Symptoms.

    Change from baseline in blinded rater assessed CGI-S at 48 hours post-first dose or at discharge/rescue therapy, if earlier was assessed. The CGI-S is a one-question rating scale which was as follows: "Considering your total clinical experience with hyponatremia symptoms in this particular population, how symptomatic is the patient at this time?" 0=not assessed; 1=normal, not at all symtpmatic; 2=borderline symptomatic; 3=mildly symptomatic; 4=moderately symptomatic; 5=markedly symptomatic; 6=severely symptomatic; 7=among the most severly symptomatic patients.

    Time frame: Baseline to 48 hours post dose

  2. Change From Baseline to 24 and 72 Hours Post Dose in CGI-S of Hyponatremia Symptoms.

    Change in CGI-S of hyponatremia symptoms from pretreatment baseline at 24 and 72 hours post-first dose, or at discharge/rescue therapy if earlier was assessed. The CGI-S is a one-question rating scale which was as follows: "Considering your total clinical experience with hyponatremia symptoms in this particular population, how symptomatic is the patient at this time?" 0=not assessed; 1=normal, not at all symtpmatic; 2=borderline symptomatic; 3=mildly symptomatic; 4=moderately symptomatic; 5=markedly symptomatic; 6=severely symptomatic; 7=among the most severly symptomatic patients.

    Time frame: Baseline to 24 and 72 hours post dose

  3. Change From Baseline to 48 Hours Post Dose in Clinical Global Impression - Improvement (CGI-I) Score of Hyponatremia Symptoms.

    Change in CGI-I score at 48 hours post-first dose or discharge/rescue therapy, if earlier was assessed. The CGI-I is a one-question rating scale where the participant is asked to rate total improvement whether or not, in their judgment, it is due entirely to trial treatment. Compared to his/her condition at admission to the trial, how much has he/she changed? 0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse

    Time frame: Baseline to 48 hours post dose

  4. Change From Baseline in Serum Sodium Concentration (24 Hour Area Under the Curve [AUC]).

    Average 24 hour AUC of serum sodium concentration change from baseline, from Day 1 Hour 0 up to 72 hours post-first dose was assessed. A serum sodium sample was drawn at pre-treament and 8, 24, 48, and 72 hours post-first dose. Serum sodium was also assessed between 36 and 72 hours after the last dose. Analysis of AUC was for daily average AUC, hence the units or AUC are mEq/L/24 hours.

    Time frame: 0 to 72 hours

  5. Time to First 2-point Improvement in CGI-S Score.

    CGI-S data up to 72 hours were used to identify 2-point improvements. Please refer to outcome measure 2 for details on the scale. For the analysis of time to first 2-point improvement in CGI-S, CGI-S data up to Hour 72 were used to identify 2-point improvements. Data for participants who received rescue therapy were censored at the time of receiving rescue therapy. For participants who were discharged before Hour 72 without reaching 2-point improvement in CGI-S, data were censored at the time of discharge. Other participants who did not reach the 2-point improvement during the 72 hours also had their data censored at their last CGI-S observations within 72 hours.

    Time frame: Up to 72 hours

  6. Percentage of Participants With Clinical Global Impression-Improvement (CGI-I) Score Improved to a Score of 1 or 2.

    Percentage of responders (defined as CGI-I score of 1 = very much improved or 2 = much improved) at 48 hours post-first dose, or at discharge/rescue therapy, if earlier. Participants given rescue therapy were given a score of 7.

    Time frame: 48 hours post dose

  7. Percentage of Participants Requiring Rescue Therapy for Hyponatremia

    Percentage of participants requiring rescue therapy within first 7 days of treatment for hyponatremia.

    Time frame: 7 days

07

Results

Posted Oct 17, 2014

Participant flow

A total of 191 participants were recruited at 81 study sites in the United States (US). A total of 124 participants were randomised to treatment.

Participant flow — Overall Study
MilestoneTolvaptan 15-60 mg/DayPlacebo
Started6658
Completed5348
Not completed1310
Withdrew: Physician decision66
Withdrew: Adverse event43
Withdrew: Withdrawal by subject30
Withdrew: Participant met withdrawal criteria01

Outcome measures

PrimaryLength of Hospital Stay (LoS)

LoS was time to clinically ready to be hospital discharged (CRBD) from study treatment initiation, disregarding prolonged hospitalization due solely to social factors.

Time frame:
45 days
Reported as:
Median · Days
Length of Hospital Stay (LoS)
DaysTolvaptan 15-60mg/DayPlacebo
Length of Hospital Stay (LoS)3.5 (3.0 to 4.5)4.0 (3.5 to 5.0)
Statistical analysis
  • Tolvaptan 15-60mg/Day vs Placebo · Generalized Wilcoxon Test · p = 0.9495 (The alpha level was set at 0.05)Participants who used rescue therapy within first 7 days of treatment period were censored at time they started the rescue therapy.
SecondaryChange From Baseline to 48 Hour Post Dose in Clinical Global Impression-Severity (CGI-S) of Hyponatremia Symptoms.

Change from baseline in blinded rater assessed CGI-S at 48 hours post-first dose or at discharge/rescue therapy, if earlier was assessed. The CGI-S is a one-question rating scale which was as follows: "Considering your total clinical experience with hyponatremia symptoms in this particular population, how symptomatic is the patient at this time?" 0=not assessed; 1=normal, not at all symtpmatic; 2=borderline symptomatic; 3=mildly symptomatic; 4=moderately symptomatic; 5=markedly symptomatic; 6=severely symptomatic; 7=among the most severly symptomatic patients.

Time frame:
Baseline to 48 hours post dose
Reported as:
Median · Units on a scale
Change From Baseline to 48 Hour Post Dose in Clinical Global Impression-Severity (CGI-S) of Hyponatremia Symptoms.
Units on a scaleTolvaptan 15-60mg/DayPlacebo
Baseline4.0 (2.0 to 6.0)4.0 (3.0 to 6.0)
48 hours post dose2.0 (1.0 to 6.0)3.0 (1.0 to 7.0)
Change from baseline-1.0 (-3.0 to 3.0)-1.0 (-3.0 to 3.0)
Statistical analysis
  • Tolvaptan 15-60mg/Day vs Placebo · ANCOVA · p = 0.1460 (alpha level was set at 0.05. p-value was derived from an ANCOVA model with treatment and clinical center as factors and baseline value as covariate.) · Mean difference (final values): -0.30 · 95% CI -0.70 to 0.11Includes factors of treatment, study center and covariate baseline.
SecondaryChange From Baseline to 24 and 72 Hours Post Dose in CGI-S of Hyponatremia Symptoms.

Change in CGI-S of hyponatremia symptoms from pretreatment baseline at 24 and 72 hours post-first dose, or at discharge/rescue therapy if earlier was assessed. The CGI-S is a one-question rating scale which was as follows: "Considering your total clinical experience with hyponatremia symptoms in this particular population, how symptomatic is the patient at this time?" 0=not assessed; 1=normal, not at all symtpmatic; 2=borderline symptomatic; 3=mildly symptomatic; 4=moderately symptomatic; 5=markedly symptomatic; 6=severely symptomatic; 7=among the most severly symptomatic patients.

Time frame:
Baseline to 24 and 72 hours post dose
Reported as:
Median · Units on a scale
Change From Baseline to 24 and 72 Hours Post Dose in CGI-S of Hyponatremia Symptoms.
Units on a scaleTolvaptan 15-60mg/DayPlacebo
Baseline4.0 (2.0 to 6.0)4.0 (3.0 to 6.0)
24 hours post-dose3.0 (1.0 to 6.0)3.0 (1.0 to 7.0)
Change from baseline at 24 hours-1.0 (-3.0 to 3.0)-1.0 (-3.0 to 2.0)
72 hours post-dose2.0 (1.0 to 6.0)2.0 (1.0 to 7.0)
Change from baseline at 72 hours-2.0 (-4.0 to 3.0)-1.0 (-4.0 to 4.0)
Statistical analysis
  • Tolvaptan 15-60mg/Day vs Placebo · ANCOVA · p = 0.3150 · Mean difference (final values): -0.19 · 95% CI -0.57 to 0.19P-value was derived from an ANCOVA model with treatment and clinical center as factors and baseline value as covariate.
  • Tolvaptan 15-60mg/Day vs Placebo · ANCOVA · p = 0.5381 · Mean difference (final values): -0.13 · 95% CI -0.57 to 0.30P-value was derived from an ANCOVA model with treatment and clinical center as factors and baseline value as covariate.
SecondaryChange From Baseline to 48 Hours Post Dose in Clinical Global Impression - Improvement (CGI-I) Score of Hyponatremia Symptoms.

Change in CGI-I score at 48 hours post-first dose or discharge/rescue therapy, if earlier was assessed. The CGI-I is a one-question rating scale where the participant is asked to rate total improvement whether or not, in their judgment, it is due entirely to trial treatment. Compared to his/her condition at admission to the trial, how much has he/she changed? 0=not assessed; 1=very much improved; 2=much improved; 3=minimally improved; 4=no change; 5=minimally worse; 6=much worse; 7=very much worse

Time frame:
Baseline to 48 hours post dose
Reported as:
Median · Units on a scale
Change From Baseline to 48 Hours Post Dose in Clinical Global Impression - Improvement (CGI-I) Score of Hyponatremia Symptoms.
Units on a scaleTolvaptan 15-60mg/DayPlacebo
Change From Baseline to 48 Hours Post Dose in Clinical Global Impression - Improvement (CGI-I) Score of Hyponatremia Symptoms.2.0 (1.0 to 7.0)2.0 (1.0 to 7.0)
Statistical analysis
  • Tolvaptan 15-60mg/Day vs Placebo · Cochran-Mantel-Haenszel · p = 0.2702 (P-value was derived from a Cochran-Mantel-Haenszel (CMH) row mean scores test.) · Mean difference (final values): -0.26 · 95% CI -0.73 to 0.21
SecondaryChange From Baseline in Serum Sodium Concentration (24 Hour Area Under the Curve [AUC]).

Average 24 hour AUC of serum sodium concentration change from baseline, from Day 1 Hour 0 up to 72 hours post-first dose was assessed. A serum sodium sample was drawn at pre-treament and 8, 24, 48, and 72 hours post-first dose. Serum sodium was also assessed between 36 and 72 hours after the last dose. Analysis of AUC was for daily average AUC, hence the units or AUC are mEq/L/24 hours.

Time frame:
0 to 72 hours
Reported as:
Least squares mean · mEq/L
Change From Baseline in Serum Sodium Concentration (24 Hour Area Under the Curve [AUC]).
mEq/LTolvaptan 15-60mg/DayPlacebo
Change From Baseline in Serum Sodium Concentration (24 Hour Area Under the Curve [AUC]).3.90 (-26.9 to 13.04)0.13 (-20.6 to 11.76)
Statistical analysis
  • Tolvaptan 15-60mg/Day vs Placebo · ANCOVA · p = 0.0019 (P-value was derived from an ANCOVA model with treatment and clinical center as factors and baseline value as covariate.) · Mean difference (final values): 3.77 · 95% CI 1.43 to 6.11
SecondaryTime to First 2-point Improvement in CGI-S Score.

CGI-S data up to 72 hours were used to identify 2-point improvements. Please refer to outcome measure 2 for details on the scale. For the analysis of time to first 2-point improvement in CGI-S, CGI-S data up to Hour 72 were used to identify 2-point improvements. Data for participants who received rescue therapy were censored at the time of receiving rescue therapy. For participants who were discharged before Hour 72 without reaching 2-point improvement in CGI-S, data were censored at the time of discharge. Other participants who did not reach the 2-point improvement during the 72 hours also had their data censored at their last CGI-S observations within 72 hours.

Time frame:
Up to 72 hours
Reported as:
Median · Hours
Time to First 2-point Improvement in CGI-S Score.
HoursTolvaptan 15-60mg/DayPlacebo
Time to First 2-point Improvement in CGI-S Score.51 (49 to 72)69 (49 to 73)
Statistical analysis
  • Tolvaptan 15-60mg/Day vs Placebo · Generalized Wilcoxon Test · p = 0.5128 (p-value was derived from Generalized Wilcoxon test stratified by treatment. Participants who received rescue therapy were censored at the time of receiving rescue therapy.)
SecondaryPercentage of Participants With Clinical Global Impression-Improvement (CGI-I) Score Improved to a Score of 1 or 2.

Percentage of responders (defined as CGI-I score of 1 = very much improved or 2 = much improved) at 48 hours post-first dose, or at discharge/rescue therapy, if earlier. Participants given rescue therapy were given a score of 7.

Time frame:
48 hours post dose
Reported as:
Number · Percentage of participants
Percentage of Participants With Clinical Global Impression-Improvement (CGI-I) Score Improved to a Score of 1 or 2.
Percentage of participantsTolvaptan 15-60mg/DayPlacebo
Percentage of Participants With Clinical Global Impression-Improvement (CGI-I) Score Improved to a Score of 1 or 2.57.852.7
Statistical analysis
  • Tolvaptan 15-60mg/Day vs Placebo · Cochran-Mantel-Haenszel · p = 0.5795 (P-value was derived using a CMH test stratified by hyponatremia symptoms severity.) · Relative risk: 1.10 · 95% CI 0.79 to 1.52
SecondaryPercentage of Participants Requiring Rescue Therapy for Hyponatremia

Percentage of participants requiring rescue therapy within first 7 days of treatment for hyponatremia.

Time frame:
7 days
Reported as:
Number · Percentage of participants
Percentage of Participants Requiring Rescue Therapy for Hyponatremia
Percentage of participantsTolvaptan 15-60mg/DayPlacebo
Percentage of Participants Requiring Rescue Therapy for Hyponatremia3.039.09
Statistical analysis
  • Tolvaptan 15-60mg/Day vs Placebo · Cochran-Mantel-Haenszel · p = 0.1568 (p-value was derived using a CMH test stratified by hyponatremia symptoms severity.) · Relative risk: 0.33 · 95% CI 0.07 to 1.65

Adverse events

Collected over Adverse events were recorded from the time the Informed Consent Form was signed up to 45 days after study drug administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Tolvaptan 15-60 mg/Day—18/66 (27.3%)52/66 (78.8%)
Placebo—9/55 (16.4%)43/55 (78.2%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventTolvaptan 15-60 mg/DayPlacebo
Renal failure acuteRenal and urinary disorders3/661/55
PneumoniaInfections and infestations2/660/55
Septic shockInfections and infestations2/660/55
HyponatraemiaMetabolism and nutrition disorders2/660/55
Rapid correction of hyponatraemiaSurgical and medical procedures2/660/55
Intestinal obstructionGastrointestinal disorders0/661/55
Upper gastrointestinal haemorrhageGastrointestinal disorders0/661/55
Staphylococcal sepsisInfections and infestations0/661/55
Femoral neck fractureInjury, poisoning and procedural complications0/661/55
Lung cancer metastaticNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/661/55
Most frequent other events
Showing 10 of 16
Most frequent other events
EventTolvaptan 15-60 mg/DayPlacebo
ConstipationGastrointestinal disorders10/666/55
HypotensionVascular disorders9/665/55
DiarrhoeaGastrointestinal disorders3/665/55
InsomniaPsychiatric disorders3/665/55
NauseaGastrointestinal disorders5/663/55
HypokalaemiaMetabolism and nutrition disorders5/664/55
Oedema peripheralGeneral disorders4/664/55
Abdominal distensionGastrointestinal disorders4/660/55
Heart rate increasedInvestigations4/663/55
HeadacheNervous system disorders4/663/55

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Tolvaptan 15-60 mg/DayPlaceboTotal
Mean65.7 ± 15.867.7 ± 15.666.7 ± 15.7
Sex: Female, Male
Sex: Female, Male(Participants)Tolvaptan 15-60 mg/DayPlaceboTotal
Female293463
Male372461
08

Study locations

56 sites
  • Otsuka Investigational Site
    Birmingham, Alabama 35216, United States
  • Otsuka Investigational Site
    Birmingham, Alabama 35242, United States
  • Otsuka Investigational Site
    Mobile, Alabama 36608, United States
  • Otsuka Investigational Site
    Azusa, California 91702, United States
  • Otsuka Investigational Site
    Banning, California 92220, United States
  • Otsuka Investigational Site
    Culver City, California 90232, United States
  • Otsuka Investigational Site
    Fountain Valley, California 92708, United States
  • Otsuka Investigational Site
    Los Angeles, California 90025, United States
  • Otsuka Investigational Site
    Los Angeles, California 90033, United States
  • Otsuka Investigational Site
    Northridge, California 91324, United States
  • Otuska Investigational Site
    Orange, California 92868, United States
  • Otsuka Investigational Site
    Yorba Linda, California 92886, United States
  • Otsuka Investigational Site
    Denver, Colorado 80210, United States
  • Otsuka Investigational Site
    Washington, District of Columbia 20010, United States
  • Otsuka Investigational Site
    Jacksonville, Florida 32207, United States
  • Otsuka Investigational Site
    Jacksonville, Florida 32209, United States
  • Otsuka Investigational Site
    Jacksonville, Florida 32216, United States
  • Otsuka Investigational Site
    Orlando, Florida 32803, United States
  • Otsuka Investigational Site
    Port Charlotte, Florida 33952, United States
  • Otsuka Investigational Site
    Savannah, Georgia 31405, United States
  • Otsuka Investigational Site
    Elizabethtown, Kentucky 42701, United States
  • Otsuka Investigational Site
    Baltimore, Maryland 21215, United States
  • Otsuka Investigational Site
    Springfield, Massachusetts 01107, United States
  • Otsuka Investigational Site
    Saginaw, Michigan 48602, United States
  • Otsuka Investigational Site
    Southfield, Michigan 48075, United States
  • Otsuka Investigational Site
    Minneapolis, Minnesota 55455, United States
  • Otsuka Investigational Site
    Rochester, Minnesota 55905, United States
  • Otsuka Investigational Site
    Jackson, Mississippi 39216, United States
  • Otsuka Investigational Site
    St. Louis, Missouri 63110, United States
  • Otsuka Investigational Site
    Grand Island, Nebraska 68803, United States
  • Otsuka Investigational Site
    Omaha, Nebraska 68131, United States
  • Otsuka Investigational Site
    Haddon Heights, New Jersey 08035, United States
  • Otsuka Investigational Site
    Newark, New Jersey 07103, United States
  • Otsuka Investigational Site
    Bronx, New York 10461, United States
  • Otsuka Investigational Site
    Buffalo, New York 14203, United States
  • Otsuka Investigational Site
    Buffalo, New York 14215, United States
  • Otsuka Investigational Site
    Jamaica, New York 11418, United States
  • Otsuka Investigational Site
    New York, New York 10032, United States
  • Otsuka Investigational Site
    Cincinnati, Ohio 45267, United States
  • Otsuka Investigational Site
    Cleveland, Ohio 44195, United States
  • Otsuka Investigational Site
    Columbus, Ohio 43212, United States
  • Otsuka Investigational Site
    Fairfield, Ohio 45014, United States
  • Otsuka Investigational Site
    Toledo, Ohio 43560, United States
  • Otsuka Investigational Site
    Oklahoma City, Oklahoma 73120, United States
  • Otsuka Investigational Site
    Bethleham, Pennsylvania 18017, United States
  • Otsuka Investigational Site
    Philadelphia, Pennsylvania 19102, United States
  • Otsuka Investigational Site
    Philadelphia, Pennsylvania 19140, United States
  • Otsuka Investigational Site
    West Reading, Pennsylvania 19611, United States
  • Otsuka Investigational Site
    Providence, Rhode Island 02903, United States
  • Otsuka Investigational Site
    Galveston, Texas 77555, United States
  • Otsuka Investigational Site
    Houston, Texas 77030, United States
  • Otsuka Investigational Site
    Mission, Texas 78572, United States
  • Otsuka Investigational Site
    San Antonio, Texas 78205, United States
  • Otsuka Investigational Site
    San Antonio, Texas 78229, United States
  • Otsuka Investigational Site
    Fairfax, Virginia 22030, United States
  • Otsuka Investigational Site
    Madison, Wisconsin 53705, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2010, a primary completion of May 2013 and a completion of May 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2010
First posted
Oct 25, 2010
Start
Oct 2010
Primary completionActual
May 2013
CompletionActual
May 2013
Results first posted
Oct 17, 2014
Last update
Oct 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01227512
Responsible party
Sponsor
First posted
Oct 25, 2010
Start date
Oct 2010
Primary completion
May 2013
Completion
May 2013
Results posted
Oct 17, 2014
Last update
Oct 30, 2014

Study contacts

Ann Dandurand, MD
study director · Otsuka Pharmaceutical Development & Commercialization, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tolvaptan

Start the discussion